BioMedNewsBreaks

WednesdayOct 14, 2026 3:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, received U.S. Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application for Lucid-MS, clearing the way for Phase 2 clinical testing of its multiple sclerosis (“MS”) candidate. The planned randomized, double-blind, placebo-controlled study will evaluate the drug’s efficacy, safety and tolerability in patients with MS, with researchers assessing clinical symptoms and changes visible through brain imaging. Unlike many existing MS therapies that target the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage,…

Continue Reading

WednesdayOct 14, 2026 2:40 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Strengthens UK Market Access and Hospital-Based AI Capabilities

Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”), an innovative technology company, is advancing Nanox.AI’s commercial and technology strategy through two developments aimed at expanding the use of AI in medical imaging. An exclusive three-year reseller agreement with Vertec Scientific, including minimum annual license commitments, establishes a dedicated UK channel for HealthOST, an AI-powered software solution that delivers qualitative and quantitative analysis of spinal CT images to help clinicians evaluate and assess spinal musculoskeletal disease, including osteoporosis. Separately, Nanox.AI has optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO, demonstrating the potential to run AI inference locally on hospital…

Continue Reading

WednesdayOct 14, 2026 10:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Completes Manufacturing of Next-Generation AI Intoxication Detection Kiosk

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, announced the completion of manufacturing for its next-generation Edge AI Intoxication Detection Kiosk. The new hardware builds on a prototype developed in June and is designed to support the company's proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment. MindBio is continuing software integration, system testing and validation of its predictive models against conventional breath alcohol and oral fluid…

Continue Reading

TuesdayOct 13, 2026 9:50 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Florida Healthcare Network With New PharmcoRx Pharmacy in Jacksonville

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions, announced the opening of a new PharmcoRx community pharmacy in Jacksonville, Florida, expanding its healthcare operations in the state. Located across from HCA Florida Memorial Hospital, the new facility offers prescription fulfillment, medication management, same-day delivery, specialty pharmacy services and patient support. The location also provides higher-margin contracted services for healthcare providers and institutions, including participants in the federal 340B drug pricing program, long-term care facilities and government agencies. PharmcoRx currently operates a network of six retail pharmacies across Florida. The expansion supports NextPlat's…

Continue Reading

TuesdayOct 13, 2026 9:10 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response. Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active…

Continue Reading

MondayOct 12, 2026 1:55 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced strong interest and engagement from orthopedic surgeons, physicians and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society ("ICRS") Summit, held Oct. 8-10 in Porto, Portugal. Discussions focused on GelrinC(R), the company's CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score ("KOOS") scores compared with historical microfracture controls at two years,…

Continue Reading

MondayOct 12, 2026 9:20 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) to Present at 2026 ThinkEquity Conference on Oct. 15

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC(R) technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration ("FDA") pivotal Phase III trial and preparations for commercialization in Europe, where GelrinC has received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings…

Continue Reading

FridayOct 09, 2026 12:53 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Builds Scalable Business Through Vertical Integration, Dual-Market Strategy

Earth Science Tech (OTC: ETST) is building a scalable, self-sustaining healthcare business through strategic acquisitions, end-to-end vertical integration, and a dual B2B and B2C revenue model. Its portfolio of pharmacies, telehealth platforms, and pharmaceutical distribution businesses connects patient consultations, clinical support, compounded medication production, and fulfillment while helping streamline operations and control supply costs. With its compounding pharmacies licensed across 34 U.S. jurisdictions, the company is expanding its reach while generating consumer-facing revenue and higher-margin business-to-business income from infrastructure and compounding services provided to third-party healthcare providers. As ETST enters fiscal 2027, management plans to expand the geographic footprint of its…

Continue Reading

ThursdayOct 08, 2026 2:35 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee cartilage treatment from symptom management toward early structural repair. Unlike microfracture, which can produce less-durable fibrocartilage, GelrinC is engineered to gradually resorb as surrounding cells regenerate hyaline-like cartilage, while avoiding cell harvesting and a second surgery. In a Phase II study, the company reported roughly 100% greater KOOS improvement versus microfracture at 24 months, along with a mean MOCART score of 88.8/100 indicating strong structural repair. With CE Mark approval in Europe, a pivotal U.S. trial targeting completion around year-end 2026, and longer-term development programs…

Continue Reading

WednesdayOct 07, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA) , a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration “FDA”-aligned New Approach Methodologies “NAMs” across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and significantly reduce animal testing. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived…

Continue Reading